Notice to readers update: provisional Public Health Service recommendations for chemoprophylaxis after occupational exposure to HIV.
Food and Drug Administration; Health Resources and Services Administration; National Institute of Allergy and Infectious Diseases; National Institute for Occupational Safety and Health; National Center for Infectious Diseases
MMWR 1996 Jun; 45(22):468-472
Based on information suggesting that zidovudine (30516871) (ZDV) may be useful as postexposure prophylaxis (PEP) to reduce the risk of human immunodeficiency virus (HIV) transmission following occupational exposure to HIV infected blood, previous Public Health Service recommendations on management of occupational exposure to HIV were updated. ZDV PEP has been credited with a 79% decrease in the risk for HIV seroconversion following percutaneous exposure to HIV infected blood in a case/control study among health care workers. In the doses currently recommended, ZDV PEP usually is tolerated well by health care workers with short term toxicity primarily including gastrointestinal symptoms, fatigue, and headache. ZDV use in the second and third trimesters of pregnancy and early infancy has not been associated with serious adverse effects in mothers or infants. The use of ZDV chemoprophylaxis should be recommended for exposed workers after occupational exposure associated with the highest risk for HIV transmission. PEP should be initiated promptly, preferably within 1 to 2 hours of exposure. If the source patient or the patient's HIV status is not known, initiating PEP should be decided on a case by case basis.
NIOSH-Author; Infectious-diseases; Disease-transmission; Disease-prevention; Health-care-personnel; Preventive-medicine; Occupational-exposure; Medical-treatment; AIDS-virus; Viral-infections; Occupational-medicine
Morbidity and Mortality Weekly Report